



RECEIVED  
APR 22 2003  
RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1615  
FAC CENTER 1600/2900

PATENT  
Attorney Docket No. 402076/SKYEPHARMA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

PARIKH et al.

Application No. 09/281,430

Art Unit: 1615

Filed: March 30, 1999

Examiner: T. Ware

For: ANTICANCER COMPOSITIONS

RESPONSE TO OFFICE ACTION

Commissioner for Patents  
Box AF  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated December 18, 2002, Applicants petition for a one month extension of time, extending the date for response to and including April 18, 2003, submit the requisite fee therefor, and request that the following remarks be considered and the referenced application be amended as shown below.

AMENDMENTS

IN THE CLAIMS:

Replace the indicated claims with:

27. (Amended) The self-emulsifying preconcentrate of claim 26, wherein the carrier system consists of 15 to 75% w/w of the hydrophobic component.

E1 28. (Amended) The self-emulsifying preconcentrate of claim 26, wherein the carrier system consists of up to 30% w/w of the hydrophilic component.

E2 30. (Amended) The preconcentrate of claim 29, wherein the hydrophilic component is selected from the group consisting of 1,2-propylene glycol and ethanol.